Selection Criteria
The 2025 EOI Period is now closed.
Unmet Need and Potential Impact
A clearly defined public health or clinical gap, supported by evidence of disease burden and end-user or patient need, and a clear articulation of how the proposed solution could deliver meaningful population-level and/or market impact
Scientific and Technical Merit
A robust scientific rationale supported by credible data that demonstrate feasibility, reproducibility, and potential for scale. The project should meet the relevant definition of Technology Readiness Level (TRL) (see Appendix) and present a credible pathway to advance to the next stage of development and/or TRL(s).
Project Plan and Budget
A well-defined, milestone-driven development plan aligned with the broader translational pathway to market, including measurable deliverables, clear go/no-go decision points, realistic timelines, and an appropriate, justified budget aligned with project scope and stage of development.
Leverage and Criticality of Biointelect Venturer Funding
A clear explanation of how Biointelect Venturer funding will be leveraged (e.g. through co-funding, partnerships, or follow-on investment) and why this support is essential at the current stage to achieve the proposed outcomes. The application should clearly demonstrate what this funding uniquely enables that existing resources cannot.
Risk and Feasibility
Identification of key competitive, technical, operational, regulatory, and commercial risks, with corresponding mitigation strategies and evidence of adaptive planning to manage uncertainties.
Competitive Positioning
A clear differentiation between this project and competing or alternative solutions, demonstrating how the innovation advances beyond current or emerging approaches in performance, usability, accessibility, or cost.
Intellectual Property
Evidence of secure or negotiable IP rights for the core technology, with a strategy to establish or maintain freedom to operate and protect commercial value.
Team Capability and Resources
A committed, multidisciplinary, and diverse team with demonstrated expertise, appropriate resources, and access to required infrastructure or partners to deliver the proposed milestones.
Consumer or End-User Consideration
Demonstrated relevance and responsiveness to end-user needs, supported by evidence of planned or existing engagement activities.
Pathway to Translation and Commercialisation
A credible route to market or partnership, including plans for follow-on funding, collaboration, or investment that support long-term sustainability and Australian sovereign capability in infectious disease prevention.
For further information on selection criteria, please refer to the Funding Guidelines.
